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OBJECTIVES: To describe the clinical outcomes and thrombotic events in a series of critically ill cancer patients positive for 
antiphospholipid (aPL) antibodies.
DESIGN: Retrospective case series study.
SETTING: Medical-surgical oncologic intensive care unit (ICU).
Patients and Participants: Eighteen patients with SIRS/sepsis and multiple organ failure (MOF) and positive for aPL antibodies, 
included over a 10-month period. 
INTERVENTIONS: None
MEASUREMENTS AND RESULTS: aPL antibodies and coagulation parameters were measured up to 48 hours after the occur-
rence of acrocyanosis or arterial/venous thrombotic events. When current criteria for the diagnosis of aPL syndrome were applied, 
16 patients met the criteria for “probable” and two patients had a definite diagnosis of APL syndrome in its catastrophic form 
(CAPS). Acrocyanosis, arterial events and venous thrombosis were present in eighteen, nine and five patients, respectively. Sepsis, 
cancer and major surgery were the main precipitating factors. All patients developed MOF during the ICU stay, with a hospital 
mortality rate of 72% (13/18). Five patients were discharged from the hospital. There were three survivors at 90 days of follow-up. 
New measurements of lupus anticoagulant (LAC) antibodies were performed in these three survivors and one patient still tested 
positive for these antibodies.
CONCLUSIONS: In this small series of patients, we observed a high frequency of auto-antibodies and micro- and macro-vascular 
thrombotic events in critically ill cancer patients. The coexistence of sepsis or SIRS and aPL antibodies was often associated with 
MOF and death. More studies are necessary to determine the pathophysiological significance of antiphospholipid antibodies in 
severely ill cancer patients.
KEYWORDS: Antiphospholipid syndrome; Multiple organ failure; Cancer; Thrombosis; Sepsis; Lupus anticoagulant.
INTRODUCTION 
Antiphospholipid (aPL) syndrome is a disorder 
characterized by recurrent venous or arterial thrombosis 
associated with distinctive laboratory abnormalities that 
include elevated levels of antibodies directed against 
membrane phospholipids (i.e., anticardiolipin [aCL] 
antibody, antiphosphatidylserine), antibodies associated 
with plasma proteins (predominantly beta-2 glycoprotein 
I), or evidence of a circulating anticoagulant (the lupus 
anticoagulant).1 The presence of aPL antibodies has 
been described in cancer patients1 and was recently 
associated with an increased rate of thrombosis and a 
worse prognosis.2,3 In cancer patients, aPL autoantibodies 
may represent a detectable link and a marker of cross-
talk between the coagulation and immune systems. The 
catastrophic aPL syndrome (CAPS, Asherson’s syndrome) 80
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is considered a rare and severe form of aPL syndrome, often 
associated with multiple organ failure (MOF) and death.4 
This autoimmune response is described in many pathologic 
situations, including infections5 and cancer,3 and results in 
the emergence of autoantibodies, such as aPL, in a permanent 
or transient manner.6 Cancer patients are frequently exposed 
to severe septic shock and systemic inflammatory response 
syndrome (SIRS).7 In acute severe illnesses like sepsis, 
major surgery and SIRS, the immune response is frequently 
implicated in the occurrence of coagulation abnormalities.8 
However, the literature to date shows very scarce data on 
the association of apL autoantibodies with the occurrence of 
life-threatening thrombotic events and multiorgan failure in 
cancer patients.
The aim of the present study was to describe the clinical 
picture and the outcomes in a series of critically ill cancer 
patients positive for aPL antibodies.
METHODS AND PATIENTS 
This was a retrospective study performed at the medical-
surgical intensive care unit (ICU) of the Instituto Nacional 
de Câncer, a multidisciplinary cancer center in Brazil. 
Information on the organization and policies of our ICU 
is described elsewhere.7 Our study was approved by the 
Institutional Review Board.
We reviewed the charts and medical records of adult 
(age ≥ 18 years) patients with a definite diagnosis of cancer 
and positive aPL antibodies, who had been admitted to 
the ICU between December 2006 and September 2007. 
Demographic, clinical, laboratory and outcome data were 
collected. Active cancer was defined as a recent diagnosis, or 
by the presence of clinical and radiologic signs of activity, or 
as any patients undergoing treatment at the time of our study 
(current chemotherapy or radiation therapy). The Simplified 
Acute Physiology Score (SAPS) II was calculated at ICU 
admission9. Sepsis was diagnosed according to the ACCP/
SCCM criteria.10
CAPS was diagnosed according to current definitions.11 
aPL antibodies were detected by ELISA (Anticardiolipin, 
standardized assay, consistent with manufacturer’s 
instructions) and clotting assay (lupus anticoagulant using 
the Russel’s Viper venom method). D-dimer, antithrombin, 
protein C, platelet count, prothrombin time, activated partial 
thromboplastin time and fibrinogen levels were determined 
using clotting assays (Dade Diagnostics, USA). aPL 
antibodies and coagulation parameters were measured up 
to 48 hours after the occurrence of acrocyanosis or arterial/
venous thrombosis in all patients. DVT was diagnosed with 
doppler and US, and gastric ischemia was diagnosed using 
endoscopy.
The decision to treat patients with corticosteroids, 
plasmapheresis or heparin was at the discretion of the 
assistant intensive care physicians and hematologists. 
Standard descriptive statistics were used. Data are 
presented as median (interquartile range 25%-75%) or 
median (range). 
RESULTS 
During the study period, a total of 540 patients were 
admitted to the ICU. Only 18 (male=13, female=5) tested 
positive for apL antibodies during their ICU stay; these 
individuals were included in the present study. The cancer 
types represented across these 18 patients included: 
gastrointestinal (n=7), larynx (n=4), non-Hodgkin’s 
lymphoma (n=3), skin/soft tissue (n=2), multiple myeloma 
(n=1) and urinary bladder (n=1). Most of the patients had an 
active malignancy (15/18). Patient group characteristics are 
shown in Table 1. All the patients fulfilled the SIRS criteria 
and had elevated plasma C-reactive protein concentrations 
on the day of diagnosis of 17.3 (13-25.2) mg/dL (median, 
25%-75% interquartile range).
Table 1 - Patient characteristics
Variables All patients (n=18)
Age (years) 71 (55 -77)
SAPS II (points) 57 (43 -64)
Main reason for ICU admission
     Severe Sepsis 15 (83%)
     Major Surgery 2 (12%)
     Hemorrhagic Shock 1 (5%)
Precipitating Factors
    Cancer  18(100%)
    Severe Sepsis 18 (100%)
    Major Surgery 6 (33%)
    Hemorrhagic Shock 1 (5%)
    HIV infection 1 (5%)
Thrombotic/Ischemic events
    Acrocyanosis 18 (100%)
    Skin necrosis (including surgical flaps) 9 (50%)
   Deep venous thrombosis  5 (28%)
    Arterial thrombosis  9 (50%)
   Cerebrovascular ischemia 5 (28%)
   Gastric ischemia 5 (28%) 
   Colonic ischemia 2 (11%)
   Splenic infarction 1 (5%)
SAPSII=Simplified Acute Physiology Score; ICU=intensive care unit. 
Results are presented as median (25%-75% interquartile range) or numbers 
(percentage).81
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Besides cancer, the main factors present were severe 
sepsis (18/18), major surgery (6/18), hemorrhagic shock 
(1/18) and HIV infection (1/18). aPL antibodies and 
coagulation tests were obtained 5 days (range: 3-12) 
after ICU admission and only one patient had a previous 
thrombotic event. All patients had positive LAC and two 
patients had high titers of aCL antibodies. The most frequent 
thrombotic and ischemic events are listed in Table 1. 
Interestingly, despite the presence of abnormal coagulation 
parameters in all patients, most of them (10/18) did not fulfill 
the International Society of Hemostasis and Thrombosis 
(ISTH) criteria for overt disseminated intravascular 
coagulation (DIC),12 or they otherwise exhibited normal 
or near-normal protein C activity levels (Table 2). When 
the diagnostic criteria were applied, 16 patients met the 
diagnostic criteria for “probable” CAPS and two had 
definite CAPS.4, 11 No patient had a previous diagnosis of 
aPL syndrome.
MOF was present in all patients. Acute lung injury and 
acute respiratory distress syndrome (18/18), cardiovascular 
collapse (18/18) and acute renal failure requiring dialysis 
(13/18) were prominent features. Despite the high prevalence 
of shock, only two patients were using extremely high doses 
(>1.0mcg/Kg/min) of norepinephrine at the occurrence of 
acrocyanosis/skin necrosis and no patient was administered 
epinephrine or vasopressin.
Treatments were administered on an individual patient 
basis, consistent with clinical assessments. Most patients 
(16/18) were treated with systemic anticoagulation using 
unfractioned heparin. Although heparin infusion did not 
seem to impact global mortality, at least four patients that 
received early anticoagulation exhibited a reversal of the 
acrocyanosis and no further major vessel thrombotic events. 
Five patients were treated with plasmapheresis. Apart from 
corticosteroids, used in low doses for sepsis, only one patient 
received high doses (1g) of methylprednisolone for three 
consecutive days.
The ICU, hospital and 90-day mortality rates were 61%, 
72% and 83%, respectively. At 90-day follow up, only 
three patients were alive. New measurements of the LAC 
antibodies were performed in these three survivors and one 
patient tested positive for the presence of these antibodies.
DISCUSSION 
In the present study we describe a small series of 
critically ill cancer patients who presented with apL 
antibodies, severe life-threatening thrombotic manifestations 
and multi-organ failure. Although the association between 
cancer and aPL antibodies is well-understood, the 
pathophysiological role of the aPL antibodies is less clear. 
Indeed, while some authors argue that these antibodies may 
be of pathological significance, others consider them an 
epiphenomenon of the malignancy. In fact, the notion that 
cancer patients positive for aPL antibodies are at high risk 
for thrombosis and have worse prognoses has only recently 
been introduced.2,3 Moreover, a recent hypothesis postulates 
that even transient aPL antibodies may be implicated in the 
pathogenesis of thrombosis.13 Only two studies addressed 
the issue of LAC antibodies in critically ill patients.14,15 
Wenzel et al., in an elegant study with 51 patients (only 
five of whom had cancer), did not observe any significant 
differences in outcomes regarding patients’ LAC antibody 
status after ICU admission.14 Sepsis and vasopressor support 
were frequently associated with LAC antibodies. However, 
no significant thrombotic events were observed during the 
study. This suggests that either these transient antibodies are 
associated with low pathogenic potential or that the study 
was insufficiently powered to detect thrombotic events. In a 
selected population of ICU patients, Aldawood et al. reported 
a frequency of 8% for transient LAC antibodies being 
associated with sepsis and mortality. However, they found 
no association between the presence of antibodies and major 
thrombotic events.15 Once again, very few cancer patients 
were evaluated and patients with hematologic malignancies 
were excluded. Heterogeneous mechanisms of coagulation 
are responsible for the increased risk of thrombosis in 
patients with cancer.16 Sepsis and SIRS have undisputable 
roles in the activation of coagulation, the development and 
amplification of endothelial activation, and microvascular 
thrombosis[8]. Therefore, it is plausible to hypothesize that 
severe pro-inflammatory and pro-coagulant insults such 
as severe sepsis may trigger catastrophic vascular events, 
especially in susceptible patients, such as those with cancer 
and positive aPL antibodies.4,5
The presence of acrocyanosis is a frequent finding in 
Table 2 - Laboratory parameters in critically ill cancer pa-
tients with antiphospholipid syndrome
Laboratory Data
     Positive Lupus anticoagulant antibody 18 (100%)
     Positive Anticardiolipin antibody 2 (11%)
     D-dimer (units/dL) 794 (271-1471)
     Protein C (activity, %) 66,5 (44-96)
     Antithrombin (activity, %) 51 (34-65) 
     Factor VIII (activity, %) 241 (198-295)
     Platelet count (x 103/mm3) 122 (73-199) 
     Fibrinogen (mg/dL) 348 (235-557)
Results are presented as median (25%-75% interquartile range) or numbers 
(percentage).82
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critically ill patients, particularly in those with septic shock, 
DIC or those requiring high doses of vasopressors. In this 
setting, acrocyanosis, skin necrosis, limb ischemia and 
thrombosis are often ascribed to micro- and macro-vascular 
occlusion. The criteria for overt DIC were present in only 
eight of our patients, and abnormalities in the anticoagulant 
protein C system were not observed in most patients (11/18). 
This not only implies that the vascular phenomena may be 
related to the aPL syndrome, but that the syndrome might 
have contributed to the development of multi-organ failure. 
We acknowledge there our study exhibits certain 
important shortcomings. We note the small sample size 
and the retrospective design. However, these are common 
flaws of studies that aim to evaluate rare diseases or unusual 
events. Ours was a retrospective and descriptive study and 
it was not designed to describe the frequency of thrombosis 
or aPL syndrome in critically ill cancer patients. Thus, 
selection bias cannot be ruled out. Patients were identified 
and included in the study because they presented clinical 
signs of severe thrombotic events. Also, the present study 
does not allow us to prove a causal relation between the 
presence of aPL antibodies and either vascular or systemic 
events. Nevertheless, most patients (16/18) fulfilled the 
diagnostic criteria for “probable CAPS” and two had 
definite diagnoses. New tests are often required to establish 
whether the antibodies are permanent or transient, and Beta-
2 glycoprotein I antibodies should be measured in future 
studies for a more robust diagnosis. However, most patients 
did not survive the 12-week period to permit a second 
measurement of LAC antibodies. Of the five patients who 
survived until hospital discharge, two died in the weeks 
following and LAC antibodies continued to test positive in 
only one of the three 90-day survivors. 
Those patients with negative antibodies had controlled 
cancer (lymphoma in remission and a resected colonic 
tumor), as opposed to the patient positive for antibodies 
who presented disease progression (rectal tumor) and was 
undergoing radiation therapy. Despite these limitations, we 
believe that the issue deserves attention and our investigation 
should be interpreted as a hypothesis-generating study.
In conclusion, CAPS may be more frequent than 
previously thought in critically ill cancer patients. In these 
patients, SIRS or sepsis coupled with aPL antibodies is 
associated with an exceedingly high number of thrombotic 
events, acute organ dysfunctions and an ominous prognosis. 
However, large prospective studies are mandatory to clearly 
establish the pathophysiological role and clinical relevance 
of aPL antibodies in critically ill cancer patients.
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